Iroko Pharmaceuticals Announces Acceptance for NDA Filing of Lower Dose Submicron Indomethacin for the Treatment of Mild to Moderate Acute Pain in Adults

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug (NSAID), for the proposed indication of treatment of mild to moderate acute pain in adults. This is the second NDA filing from Iroko’s submicron NSAID pipeline to be accepted by FDA in 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news